Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer

David M. O'Malley, Debra L. Richardson, Patrick S. Rheaume, Ritu Salani, Eric L. Eisenhauer, Georgia A. McCann, Jeffrey M. Fowler, Larry J. Copeland, David E. Cohn, Floor J. Backes

Producción científica: Article › revisión exhaustiva

45 Citas (Scopus)

Huella

Profundice en los temas de investigación de 'Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer'. En conjunto forman una huella única.

Medicine and Dentistry

Immunology and Microbiology